SUGARNSALT Study

About the SUGARNSALT Study

The purpose of the SUGARNSALT Study is to find out if a drug called sotagliflozin (SOTA) can slow kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease.

Drugs like SOTA, so called SGTL inhibitors, were initially developed to lower blood glucose in patients with diabetes. However, these drugs were later shown to have beneficial effects on kidney and cardiovascular health in people with type 2 diabetes or without diabetes. This study will look into whether these benefits are also true for people with type 1 diabetes.

The study involves

• Periodic study visits to the Joslin over 3 ½ years
• Taking 1 sotagliflozin pill or 1 inactive pill daily
• Wearing a CGM device (yours or one provided by the study)
• Monitoring blood ketone levels Blood and urine tests

All study related procedures are provided at no charge.

Monetary compensation and parking validation will be provided

Recruitment

• 18-75 years old
• Diagnosed with Type 1 Diabetes
• Have had diabetes for at least 8 years
• Your doctor has told you that you have kidney problems or albumin (protein) in your urine